rs761714818
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_021971.4(GMPPB):āc.656T>Cā(p.Ile219Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000874 in 1,613,790 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I219F) has been classified as Likely pathogenic.
Frequency
Consequence
NM_021971.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GMPPB | NM_021971.4 | c.656T>C | p.Ile219Thr | missense_variant | 7/9 | ENST00000308388.7 | |
GMPPB | NM_013334.4 | c.656T>C | p.Ile219Thr | missense_variant | 7/8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GMPPB | ENST00000308388.7 | c.656T>C | p.Ile219Thr | missense_variant | 7/9 | 1 | NM_021971.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152160Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000637 AC: 16AN: 251086Hom.: 0 AF XY: 0.0000737 AC XY: 10AN XY: 135706
GnomAD4 exome AF: 0.0000917 AC: 134AN: 1461630Hom.: 0 Cov.: 43 AF XY: 0.0000880 AC XY: 64AN XY: 727116
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152160Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74334
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 24, 2023 | Published functional studies demonstrate a damaging effect with decreased enzymatic activity as compared to wild type (Liu et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24780531, 26133662, 30684953, 26310427, 30257713, 34758253, 35006422) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 21, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | GMPPB: PM3:Very Strong, PM2, PP1, PS3:Supporting - |
GMPPB-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 13, 2023 | Variant summary: GMPPB c.656T>C (p.Ile219Thr) results in a non-conservative amino acid change located in the Nucleotidyl transferase domain (IPR005835) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 6.4e-05 in 251086 control chromosomes. This frequency does not allow conclusions about variant significance. c.656T>C has been reported in the literature as a compound heterzygous genotype in individuals affected with features of GMPPB-Related Disorders such as alpha-dystroglycanopathy, congenital muscular dystrophy, brain abnormalities and generalized epilepsy (example, PMID: 26133662, 26310427, 35006422, 24780531, 28688748). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (example, PMID: 35006422). The most pronounced variant effect results in 40% of normal GDP-mannose pyrophosphorylase B (GMPPB) activity in-vitro. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14;C3809221:Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14;C4518000:Autosomal recessive limb-girdle muscular dystrophy type 2T Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 10, 2023 | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 219 of the GMPPB protein (p.Ile219Thr). This variant is present in population databases (rs761714818, gnomAD 0.01%). This missense change has been observed in individuals with alpha-dystroglycanopathy and congenital muscular dystrophy (PMID: 24780531, 26133662, 26310427; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 575991). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GMPPB protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Abnormality of the musculature Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at